CD74 antibody

Catalog No. ABIN7865650

The Mouse Monoclonal anti-CD74 antibody (Clone LN-2) (ABIN7865650) specifically detects CD74 in FACS, IHC, IF and ICC. The antibody is reactive with Human, Mouse and Monkey samples.

Quick Overview for CD74 antibody (ABIN7865650)

Target: CD74 (HLA-DR-gamma (CD74))

Reactivity: Human, Mouse, Monkey

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD74 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunocytochemistry (ICC)

Clone: LN-2

Product Details anti-CD74 Antibody

Purpose: anti-CD74 mouse monoclonal, LN-2, purified

Cross-Reactivity (Details): negative with rat

Purification: affinity chromatography

Immunogen: cell extracts from diffuse histiocytic lymphoma SU-DHL-4

Isotype: IgG1 kappa

Application Details

Application Notes:

ICC/IF_dilution: 1:100-1:200 (0.5-1.0 μg/mL)

FACS_dilution: 0.5-1.0 μg/million cells in 0.1 ml

IHC-paraffin_dilution: 1:50-1:100 (1-2 μg/mL, microwave treatment in 10 mM citrate buffer pH 6.0 recommended)

IHC-frozen_dilution: 1:50-1:100 (1-2 μg/mL)

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 100 μg/mL

Buffer: PBS with 0.02 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: store at 2 - 8 °C

Target Details for CD74

Target: CD74 (HLA-DR-gamma (CD74))

Alternative Name: CD74

Background: LN-2 is directed against the CD74 cluster, established during the IVth Leukocyte Typing Workshops. CD74 comprises four species of proteins (MW 41/35/33 kDa), all coded by a single gene, consisting of nine exons. CD74 is expressed primarily by antigen presenting cells, such as B-lymphocytes (from before the pre-B cell stage to before the plasma cell stage), macrophages, and monocytes, and many epithelial cells. In tissue sections anti CD74 show a binding pattern very similar to that of anti-HLA-DR. It binds to the peptide binding groove of newly synthesized MHC class II alpha/beta heterodimers and prevents their premature association with endogenous polypeptides. Positive control: Daudi or Raji cells. Tonsil or lymp node.

Pathways: Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Negative Regulation of intrinsic apoptotic Signaling, Cancer Immune Checkpoints